Why 2 Studies That Used the Same Probiotic May Have Come Up With Different Outcomes

Affiliations

¹ Department of Medicinal Chemistry, University of Washington, Seattle, WashingtonUSA.
² Expert Stewardship Inc, Newport Beach, California, USA.
³ Department of Microbial and Infectious Disease, Centre Integre de Sante et de Services Sociaux de Lanaudiere, Terrebonne, Canada.
⁴ R.M. Alden Research Laboratory, Los Angeles, California, USA.

Comment

Lynne V McFarland et al. Clin Infect Dis. 2022.

. 2022 Mar 9;74(5):941-942.

doi: 10.1093/cid/ciab618.

¹ Department of Medicinal Chemistry, University of Washington, Seattle, WashingtonUSA.
² Expert Stewardship Inc, Newport Beach, California, USA.
³ Department of Microbial and Infectious Disease, Centre Integre de Sante et de Services Sociaux de Lanaudiere, Terrebonne, Canada.
⁴ R.M. Alden Research Laboratory, Los Angeles, California, USA.

No abstract available

Comment in

Reply to McFarland et al.
Heil E, Harris A, Leekha S. Heil E, et al. Clin Infect Dis. 2022 Mar 9;74(5):942-943. doi: 10.1093/cid/ciab619. Clin Infect Dis. 2022. PMID: 34240136 No abstract available.

Enhanced Clostridioides difficile Infection Prevention With a Pharmacy-Controlled Policy That Adds a 3-Strain Lactobacillus Probiotic Concomitantly to Antibiotic Therapy.
Maziade PJ, Ship N, Sniffen JC, Goldstein EJC. Maziade PJ, et al. Clin Infect Dis. 2021 Oct 20;73(8):1524-1527. doi: 10.1093/cid/ciab414. Clin Infect Dis. 2021. PMID: 33966076 Free PMC article.
A Multicenter Evaluation of Probiotic Use for the Primary Prevention of Clostridioides difficile Infection.
Heil EL, Harris AD, Brown C, Seung H, Thom KA, von Rosenvinge E, Sorongon S, Pineles L, Goodman KE, Leekha S. Heil EL, et al. Clin Infect Dis. 2021 Oct 20;73(8):1330-1337. doi: 10.1093/cid/ciab417. Clin Infect Dis. 2021. PMID: 33972996

1. Maziade PJ, Ship N, Sniffen JC, Goldstein EJC. Enhanced Clostridiodies difficile infection prevention with a pharmacy-controlled policy that adds a three-strain Lactobacillus probiotic concomitantly to antibiotic therapy. Clin Infect Dis 2021; 73:1524–7. - PMC - PubMed
1. Heil EL, Harris AD, Brown C, A multi-center evaluation of probiotic use for the primary prevention of Clostridioides difficile infection. Clin Infect Dis 2021; 73:1330–7. - PubMed
1. McFarland LV, Evans CT, Goldstein EJC. Strain-specificity and disease-specificity of probiotic efficacy: a systematic review and meta-analysis. Front Med 2018; 5:1–14. - PMC - PubMed
1. McFarland LV, Johnson S, Evans C. Perils and pitfalls of probiotic quasi-experimental studies for primary prevention of Clostridioides difficile infections: a review of the evidence. Am J Infect Control 2021; 49:375–84. - PubMed
1. Kullar R, Johnson S, McFarland LV, Goldstein EJC. Potential roles for probiotics in the treatment of COVID-19 patients and prevention of complications associated with increased antibiotic use. Antibiotics 2021; 10:408. - PMC - PubMed